MedPath

Clinical Trial of Chemosensitivity Test

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
Registration Number
NCT00287755
Lead Sponsor
Japan Clinical Cancer Research Organization
Brief Summary

To evaluate the usefulness of chemosensitivity test in evaluating the appropriate adjuvant cancer chemotherapy after gastric surgery

Detailed Description

Patients: clinical Stage III gastric cancer patients. Informed consent will be obtained before surgery. Eligible patients: surgical Stage II, IIIA and IIIB gastric cancer patients. Chemosensitivity test: The surgical specimen will be sent Mitsubishi BCL, Co. Ltd. to be tested by CD-DST chemosensitivity test and RT-PCR for thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA. The test results will be blinded for the doctors on duty.

Treatment: All the patients will be treated with S-1 at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest. The treatment will be continued until the recurrence or 1 year after operation.

Primary endpoint: 3-years disease-free survival rate Secondary endpoint: 3-years overall survival rate and side effect (CTCAE v3.0) Evaluation of chemosensitivity test: The cutoff condition will be determined based on the accumulated data of CD-DST and mRNAs.

Hypothesis: The responder detected by CD-DST and/or TS, DPD mRNA will have a favorable survival outcome comparing with resistant cases.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • histologically proven gastric cancer
  • PS (ECOG) 0 or 2
  • D2 dissection, curability B or more
  • surgical Stage IIIA and IIIB
  • negative peritoneal cytology
  • no previous radiotherapy, chemotherapy and hormone therapy
  • possible peroral intake at 6 POW
  • no severe surgical complication
  • normal bone marrow, liver and renal function
  • complete chemosensitivity test
  • written informed consent
Exclusion Criteria
  • multiple cancer
  • contraindication for S-1
  • history of drug allergy (grade 3)
  • severe complication
  • watery diarrhea
  • pregnant
  • scirrhous gastric cancer
  • the other patients who was judged as inadequate for trial by doctor on duty

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1S-1-
Primary Outcome Measures
NameTimeMethod
Overall survival rateat three years
Secondary Outcome Measures
NameTimeMethod
Side effectDuring administration of drug

Trial Locations

Locations (36)

Nagoya University Hospital

🇯🇵

Nagoya, Aichi, Japan

Gunma University Hospital

🇯🇵

Maehashi, Gunma, Japan

Hakodate Goryoukaku Hopsital

🇯🇵

Hakodate, Hokkaido, Japan

Hyogo Prefectural Awaji Hospital

🇯🇵

Sumoto, Hyogo, Japan

Ishikawa Prefectural Central Hospital

🇯🇵

Kanazawa, Ishikawa, Japan

Kanazawa Medical University Hospital

🇯🇵

Kanazawa, Ishikawa, Japan

Iwate Medical University Hospital

🇯🇵

Morioka, Iwate, Japan

Nippon Medical School Second Hospital

🇯🇵

Kawasaki, Kanagawa, Japan

St. Marianna University, School of Medicine

🇯🇵

Kawasaki, Kanagawa, Japan

Kitazato University East Hospital

🇯🇵

Sagamihara, Kanagawa, Japan

Scroll for more (26 remaining)
Nagoya University Hospital
🇯🇵Nagoya, Aichi, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.